Summary Care of the musculoskeletal system, including the muscles, joints, and bones, is important for a healthy life expectancy in today's aging society. The aim of this randomized, double-blind, placebo-controlled study was to investigate the effect of consumption of milk-fat globule membrane (MFGM) and glucosamine on joint function and physical performance. Participants were healthy Japanese men and women, aged 60-74 y, with a history of mild knee or low back pain at rest. They were randomized to receive tablets containing MFGM 1.0 g1glucosamine 1.5 g or placebo tablets for 8 wk. We assessed passive range of motion, active range of motion (self-reported VAS score), JKOM and JLEQ, and physical performance. Data were available for analysis for 25 participants in the active treatment group and 28 in the placebo group. The active group showed significant improvements in passive range of motion at the knee and active range of motion at both the knee and low back. The active group also showed significant improvements in some physical performance, including obstacle walking speed and speed of ascending stairs. The findings of this study suggest that consumption of a combination of MFGM and glucosamine may improve joint function and physical performance. Key Words knee, locomotive syndrome, low back, range of motion, walking speed Japan has one of the longest life expectancies worldwide, with an average life expectancy of 80.98 y for men and 87.14 y for women
Japan has one of the longest life expectancies worldwide, with an average life expectancy of 80.98 y for men and 87.14 y for women (http://www.mhlw.go.jp/ toukei/saikin/hw/life/life16/dL/life16-15.pdf; accessed 02 Aug 2018). However, the "healthy life expectancy," defined as the period during which an individual can perform activities of daily living without being restricted by health problems, is about a decade shorter, at 71.19 y for men and 74.21 y for women (http://www.pbhealth. med.tohoku.ac.jp/japan21/pdf/o-27-3.pdf; accessed 02 Aug 2018). This gap period exists worldwide, as 72.0 y was the average life expectancy at birth of the global population and healthy life expectancy at birth was 63.3 y in 2016 (http://apps.who.int/gho/data/node. main.688?lang5en; accessed 04 Dec 2018). During this approximately 10-y interval, physical disability is one of the main factors leading to the need for assisted living. Musculoskeletal disorders and their consequences have been reported to account for 20% of all factors that can lead to an elderly individual needing care (https://www. mhlw.go.jp/english/database/db-hss/cslc-index.html; accessed 02 Aug 2018). "Locomotive syndrome" is a concept proposed by the Japanese Orthopaedic Association to describe a state in which mobility is diminished because of impairment of the musculoskeletal system (1) . This syndrome is likely to be an important determinant of healthy life expectancy. The musculoskeletal system includes muscles, nerves, joints, and bones, all of which must work in synchrony to maintain healthy physical activity.
Ota et al. have reported an improvement in muscle cross-sectional area and strength in response to a combination of dietary supplementation with milk-fat globule membrane (MFGM) and exercise training (2) (3) (4) . MFGM is a structural membrane that covers the globules of triglycerides dispersed in an emulsion in milk and contains membrane-specific proteins, phospholipids, and sphingolipids (5) . MFGM is reported to be useful for improving not only muscle function but also some aspects of physical performance, including agility, balance, and walking ability (3, 6, 7) . These effects have been suggested to be attributable to improvement of motor unit activity at the neuromuscular junction (2, 4) and sphingomyelin in the MFGM may contribute to its functions (8) . Although the influence of MFGM on the neuromuscular aspects of physical performance has been investigated, its effects at the level of the joints, which are important components of the musculoskeletal system, are currently unclear. Because voluntary skeletal muscle also has an essential role in joint mobility (9), MFGM, which affects neuromuscular function, may be expected to improve the function of the joints.
On the other hand, glucosamine is a dietary com-ponent that is thought to have protective effects on articular cartilage. For example, glucosamine has been reported to improve Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores in patients with osteoarthritis of the knee (10) and to improve mild knee pain in otherwise healthy individuals (11) . The aim of this study was to evaluate how consumption of a combination of MFGM (for neuromuscular conditioning) and glucosamine (for maintenance of articular cartilage) may influence joint function and associated physical performance.
MATERIALS AND METHODS
Participants. Participants were healthy Japanese men and women aged 60-74 y with a knee pain and low back pain at rest. Individuals with osteoarthritis, rheumatoid arthritis, gout, severe liver dysfunction, cardiovascular disease, endocrine disorder such as diabetes, and other systemic disease were excluded, along with those who were deemed unsuitable for participation by their attending physicians. The sample size was calculated using the method described by Ota et al. (3) that evaluated the influence of MFGM on physical performance. We calculated that 22 participants per group would be required for an alpha error rate of 5% and a beta error rate of 20%. Therefore, the recruitment target was set at 30 per group. All participants provided written informed consent after receiving a detailed written explanation of the study protocol, characteristics, objectives, and potential risks.
Ethics and management. This study was performed at the Kouki Medical Clinic (Sapporo, Japan) from January 2017 to March 2017 in accordance with the Declaration of Helsinki (2013), managed by a contract research organization, Medical Corporation Jikokai (Sapporo, Japan). All the protocols were approved by the Fukuzumi Internal Medicine Clinic Ethics Review Committee (Approval no: g2016027; Approval date: 5 December 2016), and were registered with the UMIN Clinical Trial Registry before the enrollment of the first participant (UMIN000025660).
Materials. Participants in the active treatment group received eight tablets containing 1.0 g of MFGM (38 mg as sphingomyelin; Arla Foods, Aarhus, Denmark) and 1.5 g of glucosamine hydrochloride (Koyo Chemical Co., Osaka, Japan). Participants in the placebo group received eight tablets that were identical in shape, taste, and texture to the active tablets but without both MFGM and glucosamine. The tablets were produced by direct compression of mixtures for this study and the composition of the tablets is shown in Table 1 .
Study protocol. The study had a randomized, doubleblind, placebo-controlled, parallel-group design and duration of 8 wk. Measurements were performed at baseline (week 0) and after 4 and 8 wk of intervention. Before the baseline measurements, each participant completed a screening test that involved a knee X-ray, anthropometric measurement, Japanese Knee Osteoarthritis Measure (JKOM) (12) and VAS for knee and low back pain at rest, and 10-m walking speed. Following the test, the participants were enrolled by their attending physicians if they met the study eligibility criteria.
The participants were randomized using computergenerated random numbers into two groups according to their JKOM and VAS scores for knee and low back pain. One group received the active tablets and the other group received placebo tablets. The allocation list was strictly sealed, and participants and staff remained unaware of the allocation throughout the study.
Each participant took 8 of the allocated tablets once daily for the 8-wk study period. No particular time of day for taking the tablets was specified, but participants were asked to record the time they took the tablets in a daily log. At the baseline and week 4 assessments, participants took their tablets after the tests, and at the week 8 assessment, they were instructed to discontinue the tablets.
The participants were instructed to maintain as much as possible their usual dietary, exercise, smoking, and drinking habits and other aspects of daily life during the study period. They were also instructed to avoid taking any supplements that could potentially influence the results of the study. If taking other pharmaceutical products was unavoidable, they were asked to record the details in the daily log.
Tests.
(1) Anthropometric measurements: Body weight, systolic and diastolic blood pressure, pulse rate, and temperature were measured at the screening test and at baseline, week 4, and week 8. Body height was recorded once at the screening test.
(2) Range of motion: Passive and active range of motion were measured at baseline and weeks 4 and 8. The passive ranges of motion for knee flexion and low back rotation were measured by an orthopedic specialist. Active range of motion was measured using the selfreported VAS score.
(3) JKOM JLEQ: and pain. The function of the knee joint was assessed using the JKOM (a functional evaluation scale for patients with osteoarthritis) at baseline and at week 4 and 8. Low back pain and knee pain (at rest and while walking or running) were assessed using VAS and the Japan Low Back Pain Evaluation Questionnaire (JLEQ; for functional evaluation of low back pain) (13) also at baseline and at week 4 and 8. ogy and biochemistry parameters were analyzed: white blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, creatinine, uric acid, creatine kinase, total cholesterol, high-density and low-density lipoprotein cholesterol, triglycerides, fasting blood glucose, and C-reactive protein. The urinary parameters measured were specific gravity, pH, ketone bodies, occult blood, urobilinogen, bilirubin, protein, and glucose. (6) Daily activity levels: All participants recorded the number of steps taken daily using a pedometer (Active style PRO HJA-750C; Omron Healthcare Ltd., Kyoto, Japan), starting 1 wk before the baseline assessment and throughout the study period.
(7) Daily log and interview: One week prior to baseline and from baseline through to week 8 of intervention, participants completed a daily log that they gave to the investigator at each assessment. The log comprised subjective symptoms, details of any medication taken, and tablet consumption rate. A physician interviewed the participants to evaluate their subjective symptoms and record objective findings.
Statistical analysis. Anthropometric measurements, passive range of joint motion, self-reported active range of joint motion, JKOM and JLEQ scores, VAS pain scores, and physical performance were analyzed using a linear mixed model with the effect of time (baseline, week 4, week 8) and interaction between groups (active, placebo) as the covariates, as well as the Bonferroni post hoc test. The initial values were used as covariates for the anthropometric measurements, passive range of joint motion, JKOM and JLEQ scores, VAS pain scores, and physical activity was used as the covariate for physical performance. Student's t-test was used to compare the hematology and biochemistry parameters within the groups, and the between-group analysis was performed using a linear mixed model with the initial values as the covariates. Student's t-test was used to compare tablet consumption rate and physical activity between the groups during the study. The level of significance was set as 5% for all statistical tests. All statistical analysis was performed using SPSS Statistics version 19 software (SPSS Japan Inc., Tokyo, Japan). Figure 1 shows the flow of participants through the study. Of 257 participants who underwent screening, 197 were excluded because they did not meet the eligi- bility criteria, leaving 60 for randomization to the two arms. After randomization, one participant who took medication for arthralgia was withdrawn, leaving 59 patients who completed the study (active group, n529; placebo group, n530). Of those who completed the study, two participants had a low tablet consumption rate, two violated the study protocol (continued use of analgesics), and two had low initial VAS scores for knee pain. Finally, data on physical performance and joint function was analyzed for 53 participants (active group, n525; placebo group, n528; Per protocol set). To evaluate safety, 59 patients who completed the study were analyzed (Full analysis set). The mean tablet consumption rate was 99.860.6% in the active group and 99.6%60.8% in the placebo group. There was no significant difference in the mean number of steps taken per day during the study period between the groups (5,644.862,066.0 vs. 5,102.562,038.7, respectively). Table 2 shows the anthropometric measurements. Body weight, body mass index, pulse rate, and temperature did not differ significantly between the groups. Systolic and diastolic blood pressure value decreased significantly from baseline to week 8 in the placebo group, but there was no between-group difference.
RESULTS

Participants
Anthropometric measurements
Range of motion Table 3 shows the results for passive range of joint motion. Knee flexion range of motion and low back rotation range of motion increased significantly from baseline to week 8 in both groups. There was a significant group-by-time interaction for knee flexion range of motion. Table 4 shows the results for subjective symptoms. The active treatment group showed a significant increase in range of flexion and straightening the knee and ease of knee movement from baseline to week 8, with a significant difference in the group-by-time inter- action. Both groups showed significant increases in range of bending forward, range of bending backward, range of twisting the low back, and ease of low back movement from baseline to week 8, with a significant difference in the group-by-time interaction.
JKOM and JLEQ
The JKOM and JLEQ scores are shown in Table 5 . Both scores decreased significantly from baseline to week 8 in both groups; however, there were no significant differences between the groups. Pain items, including resting knee pain, resting low back pain, knee pain while walking, low back pain while walking, knee pain while ascending/descending stairs, and low back pain while ascending/descending stairs, showed significant decreases in VAS scores for all items in both groups from baseline to week 8, but there were no significant between-group differences ( Table 5) .
Physical performance
The results of the physical performance evaluation are shown in Table 6 . Seated open-close stepping test, 10-m normal walking speed, 10-m maximum walking speed, 10-m obstacle walking speed, ascending stairs, and descending stairs improved significantly in both groups from baseline to week 8. In addition, there was a significant difference in the group-by-time interaction for 10-m obstacle walking speed and ascending stairs. Maintaining one-legged stand with eyes open increased significantly from baseline to week 8 only in the active group; there was no significant between-group difference. Furthermore, there was no significant change in the one-legged stand with eyes closed over the study period in either group and no significant between-group difference.
Blood and urine investigations (For safety evaluation)
The results of the blood test for the 59 participants who completed the study are shown in Table 7 . There was a significant decrease in hematocrit and mean corpuscular volume in both groups from baseline to week 8. There were significant changes in mean corpuscular hemoglobin concentration, alanine aminotransferase, and gamma-glutamyl transpeptidase in the active treatment group and in creatinine and fasting blood glucose in the placebo group. A significant difference was observed in alanine transaminase, gamma-glutamyl transpeptidase and creatinine between the active and placebo. No intragroup or intergroup changes were detected in any of the urinary parameters.
Adverse events
There were 22 adverse events in the active treatment group (12 respiratory infections, 1 feebleness, 2 headache, 1 stomachache, 3 joint pain, 1 constipation, 1 gastric distress, 1 dry mouth) and 30 in the placebo group (8 respiratory infections, 3 feebleness, 3 headache, 1 stomachache, 9 joint pain, 2 shoulder tightness, 1 constipation, 1 hard stool, 1 diarrhea, 1 gastric distress). There was no significant difference in the incidence of adverse events between the groups. All symptoms were transient and mild and did not require discontinuation of the test tablet or additional treatment. The attending physicians determined that there was no relationship between the adverse events and tablet consumption.
DISCUSSION
This study investigated the effect of 8 wk of continuous consumption of MFGM1glucosamine on joint function and associated physical performance. Range of motion is a measure of joint function that can be either passive or active (9) . In this study, both passive and active range of motion of the knee improved significantly in participants who consumed MFGM1glucosamine, and there was a significant group-by-time interaction. Glucosamine has been reported to have a positive effect on the synthesis and degradation of cartilage (14-17) and a stimulatory effect on production of hyaluronic acid in the synovium (18) . In a study performed in young athletes, 4 wk of glucosamine consumption improved the passive range of motion in injured knees (19) . Thus far, there are no reports of glucosamine improving the active range of motion at any joint. However, there are reports of MFGM combined with light exercise improving muscle strength in both mice and humans (2) (3) (4) 8) and improving motor coordination via the neuromuscular junction (20) . The sphingomyelin contained in MFGM is thought to play a role in these effects (8) . The active range of joint motion is influenced by muscle strength and motor coordination and by the antagonist muscles (9) , and the range of knee movement during exercise has been reported to be improved by resistance training (21) . Therefore, the improvements in active range of joint motion demonstrated in this study may be the combined effect of glucosamine on the joints and the effect of MFGM on the muscles surrounding the joints and at the level of the neuromuscular junction. Consumption of MFGM1glucosamine improved the active range of motion at the low back in this study. The low back joint contains less cartilage than the knee joint (22) , so the surrounding musculature is thought to have a greater impact on movement than the cartilage. Therefore, the active range of motion at the knee was thought to be improved by the combined consumption of MFGM1glucosamine, which probably could not have been achieved by glucosamine alone.
Obstacle walking speed and speed of ascending stairs were improved in the active group that received MFGM 1glucosamine, and there was a significant groupby-time interaction. Improvement of obstacle walking speed 0.05 m/s (vs placebo) is a small but important effect, considering that in 5 y, its average speed could be decreased by about 0.1 m/s (http://www.mext.go.jp/ sports/b_menu/toukei/chousa04/tairyoku/kekka/k_ detail/1409822.htm; accessed 04 Dec 2018). Obstacle walking speed is a measure of physical strength and includes leg muscle strength, balance, agility, and walking performance and is known to relate to activities of daily living (23) . Combination of MFGM with exercise has previously been reported to improve obstacle walking speed (7) , and this is thought to be an effect of increased muscle strength and mass (2-4) and improved balance and agility (6, 7) . In our study, the blood creatinine level which is used as a surrogate of muscle mass (24) was increased only in placebo group. So the increased muscle strength rather than muscle mass may contribute to improvement of obstacle walking speed in active group. Furthermore, range of joint motion is related to walking speed (25) , and joint care supplements that contain glucosamine or chondroitin were shown to improve walking speed in individuals experiencing knee pain (26, 27) . Therefore, our results suggest that the intake of MFGM, which effects on physical function and glucosamine, which effects on joint function had a beneficial effect on obstacle walking speed and speed of ascending stairs.
The VAS pain, JKOM, and JLEQ scores were used to assess subjective symptoms. All of these measures decreased after intervention, but without any significant differences between the two groups. Therefore, it can be assumed that improvements in range of joint motion or physical function were not greatly affected by a decrease in pain levels.
Adverse events such as cold-like symptoms, headaches, and stomachaches occurred during the study but were not severe enough to warrant withdrawal. There was no difference in the adverse event rate between the groups, and none of the adverse events were considered by the principal investigator to be related to tablet consumption. There were no abnormal changes in parameters of liver function, renal function, hematology or biochemistry tests of blood sample, or urinary tests. Therefore, we conclude that consumption of MFGM 1glucosamine is safe.
There are several limitations to this study. First, the study duration was shorter than in previous investigations of the effect of glucosamine consumption on the joints (10, 11) . Therefore, we need to assess the longterm effects of MFGM1glucosamine in the future. Second, the study did not include a group who received MFGM alone, so we were unable to clearly distinguish between the effect of glucosamine and that of MFGM. We also need to investigate whether the magnitude of change in range of joint motion is clinically significant. In summary, our findings demonstrate that consumption of MFGM with glucosamine improves joint function and physical performance. The safety of this combination was also confirmed. The combination of MFGM with glucosamine is expected to become a new strategy for the prevention of locomotive syndrome in the future.
